Neurohawk fight back

Bullmore et al argue for psychiatry to continue to develop as a neuroscientific discipline, rebutting what they describe as ‘neurophobic’ views of mental illness. I share their enthusiasm for further understanding the biological basis of psychological conditions, and the article highlights an unhealthy division that continues to cause debate and disagreement in those treating mental illness. It often manifests itself in day-to-day clinical practice and is expressed by those that view mental illness as ‘psychological’ and those that look for a ‘biological’ explanation. Obviously the two cannot be separated – unless clinging to a Descartian dualistic viewpoint, one must be optimistic that all mental life will eventually be mapped onto a neuronal substrate.

Proponents of both approaches would do well to familiarise themselves with David Marr, acknowledged as the founder of computational neuroscience, and his concept of ‘levels of analysis’ which he applied to his seminal explanations of the visual system’s information processing. He pointed out that one must be aware of the ‘level’ at which one is trying to explain a problem. Bullmore et al urge us to find explanations to mental functioning at the implementational level involving the biological substrate, i.e. genes, molecular and cellular interactions creating a complex system. Theories put forward by Beck and Seligman on explaining depression, for example, and Clark’s work on panic disorder are set at a higher level of explanation and do not address the implementation of the processes. For example, Clark postulated that it is a catastrophic interpretation of body state that leads to a panic attack. This level of explanation offers a psychological mechanism but does not comment on the biological underpinning of the disorder. This does not mean that Clark’s explanation of panic attacks claims the disorder to be ‘psychological’ rather than ‘biological’. Instead, the explanation is set at a computational level and not an implementational level.

To understand that brain-based and psychological explanations are not mutually exclusive but that they offer different levels of explanation will help avoid unnecessary debate. We can no more afford to be ‘neurophobic’ than we can afford to be ‘psychophobic’; understanding at every level is vital in moving psychiatry forward as a discipline of medicine.

but later on admit that the true mechanism of action of psychiatric drugs and the pathophysiology of mental disorders are unknown. Despite this, they conclude by advocating for more psychopharmacology in the MRCPsych curriculum.

Bullmore et al correctly highlight the false dichotomy between functional and organic disorders. However, they fail to acknowledge that disorders previously conceived as psychiatric, for which a neuropathology has been elucidated, are now considered neurological disorders and the preserve of neurologists. Huntington’s disease and neurosyphilis are two examples. Consequently, they do not consider whether, if future neuroscientific research elucidates a neuropathology for the major mental disorders, these disorders would still be under the remit of psychiatrists. If not, perhaps there is little need for clinical psychologists to embrace the neurosciences.

They further note that objections to neurobiological research are based on concerns that the doctor–patient relationship would be fundamentally altered, to the patient’s detriment. They argue that this is not the case for other medical specialties, where empathy and understanding are still important. However, they fail to acknowledge that disorders previously conceived as psychiatric, for which a neuropathology has been elucidated, are now considered neurological disorders and the preserve of neurologists. Huntington’s disease and neurosyphilis are two examples. Consequently, they do not consider whether, if future neuroscientific research elucidates a neuropathology for the major mental disorders, these disorders would still be under the remit of psychiatrists. If not, perhaps there is little need for clinical psychologists to embrace the neurosciences.

They note the contention that physical models have not made any difference to clinical psychiatry, yet they provide no defence, only an optimistic future prediction that this will happen. It is difficult to object to neurobiological research into psychiatry, and although psychopharmacology is one of the success stories of modern psychiatry, our drugs are the result of serendipity rather than a true understanding of the neural and molecular basis of the mental phenomena that underpin the experiences diagnosed as mental disorder. This research is extremely expensive and may be occurring at the cost of social, epidemiological and psychological research for which it is increasingly difficult to secure funding. In contrast, such research has created evidenced-based interventions for mental illness. For example, the finding that high expressed emotion in families is associated with greater relapse in schizophrenia led to the development of family intervention, and the finding that life events of an interpersonal nature were associated with the onset of depression led to the development of interpersonal therapy. Perhaps psychiatry cannot afford to be neurophobic, but no evidence for this has thus far been provided.


Psychiatry rests on the biopsychosocial model rather like a three-legged stool: remove any one of the legs and the stool, and psychiatry, fall over. Another three-legged stool might be that of emotion, cognition and behaviour, each is necessary, but insufficient, for understanding humans.

In ‘Why psychiatry can’t afford to be neurophobic,’ Bullmore et al give a compelling picture of the complexity and explanatory power of genotype and phenotype in modern psychiatry and neuroscience. They expand phenotype to include behaviour and cognition, and also refer to Reil’s vision of psychiatrists as physicians of the mind. Reil (1759–1813) coined the term ‘psychiatry’ and was concerned with the soul and soul organ, which he considered to be a product of the nervous system.2 Reil’s conception of the soul would be considerably wider than cognitive function and behaviour. Living during the Romantic period, he was concerned with what today might be called emotions, character and self-regulation.

It is difficult to do justice to the full breadth of neuroscience in an editorial; however, neuroscience and psychiatry are far broader than genes, cognition and the intervening processes. Although the nod is given to psychoanalysis and the importance of ‘mental, interpersonal, developmental and therapeutic processes’, and ‘maternal deprivation and child abuse’, there is no reference to emotion and its mental representation, affect, and the rapidly growing fields of affective neuroscience, attachment theory, affect regulation, mentalisation and developmental psychopathology.

Biological, ethological and paleoanthropology have shown that social living has been the most important recent evolutionary pressure for brain development.1 Subjectivity is intrinsic to, and an emergent property of, our social brain.4 Ethology and attachment theory have shown how emotions are the glue of social interactions; from the moment of birth we are instinctually driven to engage with others: attachment behaviours, smiling and crying are genetically programmed. The representation of affect states in self and other (mentalisation) is vital to affect regulation and effective social adaptation; affect regulation and mentalisation are acquired through secure attachment relationships; and secure attachment, mentalisation and self-regulation contribute significantly to emotional resilience, which helps us to weather the challenges that life presents.5,6

The danger of seeming to neglect the importance of emotion and relating (while emphasising the importance of cognition, molecules and genes) in psychiatry is that we risk promoting the disengagement from neuroscience that Bullmore et al argue so passionately against.


Daniel McQueen. The Cassel Hospital, Emerging and Severe Personality Disorder Service, 1 Ham Common, Richmond, Surrey TW10 7IF, UK. Email: daniel.mcqueen@wmht.nhs.uk
doi: 10.1192/bjp.195.3.269

Authors’ reply: We thank the correspondents for their interest in our article that, following Craddock’s polemic,2 we hoped would provoke some responses and debate. While we would dearly

Vivek Datta. Division of Psychological Medicine, Institute of Psychiatry, King’s College London, UK. Email: vivek.datta@doctors.org.uk
doi: 10.1192/bjp.195.3.268b
like to agree with the Editor’s suggestion that a belief in the importance of the brain marks us out as Cavaliers, we fear that the neuroscientific enterprise, marked by slow, painstaking data collection, hypothesis testing and incremental advances does not quite suit his analogy. Nor do we, in championing neuroscience, dismiss the importance of other levels of explanation as some of our respondents suggest. Our original editorial was clear on this. As for the suggestion that neuroscience is a form of behaviourism and must thereby deny the mind, we do hope that a brief survey of the past decade’s cognitive neuroscience literature refutes that concern.

McQueen is right to take us to task for forgetting emotion: this is an oversight in our article but not, we are happy to say, in the field, where affective and social neurosciences thrive. Blewett is also correct when he points out that major impacts on the lives of patients have arisen and continue to flow from phenomena that are meaningless when conceived solely within a neuroscientific framework.

We certainly do not denur from a biopsychosocial formulation; these are the three primary colours in which we paint our discipline and which make it more vibrant than other medical specialties. Rather, we point out that the ‘bio’ aspect of psychiatry is getting brighter, stronger and, in our opinion, more useful such that, as a profession, we cannot afford to ignore it lest we do a disservice to our patients. To argue, as does Datta, that if we embrace this change then we shall be taken over by neurology is surely, as Johansson indicates, unfalteringly absurd.

After all, patients need good doctors first and foremost, and we believe that Reil conceived psychiatry as a broad discipline reflecting his own polymathematical abilities.

When we manage someone’s arachnophobia with an appropriately eclectic mix of graded exposure, a selective serotonin reuptake inhibitor for comorbid depression, psychoeducation and family support we do not aim for them to live in a world populated by tarantulas, let alone become one. So, too, for McQueen is right to take us to task for forgetting emotion: this is an oversight in our article but not, we are happy to say, in the field, where affective and social neurosciences thrive. Blewett is also correct when he points out that major impacts on the lives of patients have arisen and continue to flow from phenomena that are meaningless when conceived solely within a neuroscientific framework.

We certainly do not denur from a biopsychosocial formulation; these are the three primary colours in which we paint our discipline and which make it more vibrant than other medical specialties. Rather, we point out that the ‘bio’ aspect of psychiatry is getting brighter, stronger and, in our opinion, more useful such that, as a profession, we cannot afford to ignore it lest we do a disservice to our patients. To argue, as does Datta, that if we embrace this change then we shall be taken over by neurology is surely, as Johansson indicates, unfalteringly absurd.

After all, patients need good doctors first and foremost, and we believe that Reil conceived psychiatry as a broad discipline reflecting his own polymathematical abilities.

When we manage someone’s arachnophobia with an appropriately eclectic mix of graded exposure, a selective serotonin reuptake inhibitor for comorbid depression, psychoeducation and family support we do not aim for them to live in a world populated by tarantulas, let alone become one. So, too, for psychiatry: in pointing out its neurophobic tendencies we aim to restore good function and allow it to move on. To us, this doesn’t appear to be rocket science, just neuroscience.

Psychopathic traits and studies of deception

Fullam et al’s aim was to investigate the relationship between neural responses during deception and psychopathic personality traits. One of my main concerns is that what the authors referred to as ‘deception’ was not actually deception. The study participants were aware that the truth was known and they were being asked to ‘lie’ for the study. I do not believe this to be a good enough surrogate for deception.

For the purpose of the study, the word ‘lie’ was defined as ‘the intentional giving of a false response and awareness that the response is false rather than a mistake’. I believe this definition to be inadequate. The definition does not take into account that participants were ‘told’ to provide untrue answers or the fact that the true answers were known by the assessors. This situation is more comparable to a dramatic performance or acting rather than deception. A more appropriate definition of a lie would include the intent to deceive that is always present in a lie. These participants did not intend to deceive anyone with the ‘false’ answers, so they cannot be seen as lying.

Furthermore, the study adopts an approach that does not take into account the emotional and contextual elements involved in deception. The consequences of lying or not lying during the study were also incomparable to real life. This reduces the ecological validity of the study and makes the findings difficult to generalise.

The participants were also ‘required’ to make a motor response in order to select their answer. This adds further complexity to the analysis of the study results and further dents the ecological validity.

One of the main findings was that ‘mean response times (seconds) were significantly slower during the lie condition’. Although the stated F-value (0.024) shows a statistically significant difference, the actual difference of a tenth of a second (the difference between 2.66 and 2.56 seconds) only equates to about 4% delay. In clinical terms this does not appear to be significant.

The functional magnetic resonance imaging (fMRI) does provide exciting opportunities for research, but the overall utility of this study appears to be very limited; further research of a higher quality is required in this fascinating but complex field.

To overcome some of the problems with the methodology, the researchers would actually have to deceive the participants regarding the aims of such a study. The British Psychological Society provides extensive guidance regarding the use of deception in research (www.bps.org.uk/the-society/code-of-conduct/ethical-principles-for-conducting-research-with-human-participants.cfm).


Authors’ reply: Dr Ehjaz appears to have misinterpreted the purpose of our study and his comments suggest a lack of awareness of the extensive literature examining the utility of fMRI for the detection of deception.1–4

The primary goal of our study was to examine the influence of psychopathic personality traits on neural responses exhibited during deception. We used a direct replication of a previously published simple deception paradigm developed by Spence et al5 and our definition of deception was lifted directly from Spence’s work in this area. We have clearly acknowledged in the paper that the work presented needs to be replicated with more sophisticated paradigms, including those with an emotional component. The issues surrounding deception paradigm design are adequately covered in the existing literature.

Dr Ehjaz states that our main findings were the reported reaction time differences between the lie and truth conditions. This is not correct. The key findings lie in the modulation of deception-related blood oxygen level-dependent responses by personality traits. The response time data are reported as a direct replication of Spence et al’s5 finding and indicate increased cognitive load associated with the production of a lie at the same time as withholding a truthful response. In neural terms, a mean response time difference of a tenth of a second is really rather significant.
Lithium in drinking water and food, and risk of suicide

Ohgami et al reported lithium in drinking water (0.7–59 gm/l) and linked it to suicide rates. However, dietary lithium, which has received scant attention, is found in grains and vegetables, and to some extent animal-derived foods. Hence, considering only lithium in drinking water may not be enough of a link to suicide rates. Dietary sources of lithium may actually have made the difference rather than just the drinking water. Differences in the prevalence of mood disorders with natural lithium levels acting as a prophylactic have been reported. Jathar et al assessed the lithium content of the daily diet (72.55–154.6 μg/g) and biological fluids, and hypothesised lithium to be a natural prophylactic. It will be interesting to see whether dietary and drinking water lithium levels have a direct impact on mood disorder prevalence, which in turn could explain the variation in suicide rates. And what about lithium-containing food cooked in lithium-containing tap water?


Correspondence

Authors’ reply: We thank Drs Chandra and Babu for their comments, but we would like to emphasise that we had never recommended the addition of lithium to drinking water supplies because our findings are preliminary and yet to be conclusive.

First, we agree that sociological factors such as migration, poverty, human relations and economic issues may be associated with suicide rates, and have already admitted such limitations by stating ‘other factors such as psychosocial and economic factors were not taken into consideration’. Second, Drs Chandra and Babu state that it is also important to assess side-effects of lithium in tap water on thyroid function, pregnant women and the unborn fetus. Although it seems probable that these low levels of lithium are far below the levels required to produce side-effects, we agree with them. Third, they mention lithium levels in food, also raised by Drs Desai and Chaturvedi. This may be important because dietary lithium intake is estimated not to be a negligible quantity. For example, mean (s.d.) dietary lithium was reported to be: 1560 μg/day (980) in China; 1485 (1009) (Tijuana) and 939 (928) (Culiacan) in Mexico; 1090 (324) in Sweden; 1009 (324) in Denmark; 821 (684) (Texas), 650 (740) (New York) and 429 (116) (San Diego) in the USA; 812 (383) in Japan; 406 (383) in Germany; and 348 (290) in Austria. Therefore, at the next stage,
it would seem necessary to measure serum lithium levels in participants, incorporating total lithium intake of both drinking water and food.


Psychosis and catatonia as a first presentation of antiphospholipid syndrome

We report (with the patient’s consent) a 28-year-old woman who presented with episodic psychosis and catatonia associated with antiphospholipid syndrome, with venous thromboembolism, rash, an acute phase response, and elevated liver enzymes. We know of no previous reports of catatonia associated with this syndrome.

She was admitted abroad in October 2007 with rapid-onset psychosis (perseveratory delusions, visual/auditory hallucinations), confusion, and disorientation. She responded to quetiapine and lorazepam, and initially remained well after stopping medication. In July 2008 she deteriorated, with low mood, somatic and nihilistic delusions, and demotivation. She was admitted with catatonic stupor, staring and mutism. She improved with haloperidol, exhibiting severe distraction with thought block and hypersensitivity to background noise, before recalling visual/auditory hallucinations, confusion and delusions. In August 2008 she suffered a spontaneous popliteal vein thrombosis and a mild purpuric rash.

She had no personal or family history of psychiatric, autoimmune or thromboembolic disease, did not smoke or use recreational drugs, and took no medication except an oral contraceptive.

She had persistent elevations in alanine aminotransferase (79 U/L prior to quetiapine, peak 257 U/L), erythrocyte sedimentation rate (19–24 mm/h), and C-reactive protein (17 mg/l). Hepatic ultrasound showed mild diffuse echogenicity. Anticardiolipin antibodies were positive (22 IgM U/ml, August 2008; 25.4 IgG U/ml, October 2008; 18.0 IgM U/ml, November 2008 after immunosuppression). Antinuclear antibody was negative from 25.4 IgGU/ml, October 2008; 18.0 IgMU/ml, November 2008 after lipin antibodies were positive (22 IgMU/ml, August 2008; 40.0 IgGU/ml, October 2008). She was anticoagulated further (international normalised ratio 3:4) for the thrombosis.

She was admitted in October 2008 with severe agitation, paranoia, thought block, confusional state, and disorientation. She responded to quetiapine and olanzapine, and initially remained well after stopping medication. In July 2008 she deteriorated, with low mood, somatic and nihilistic delusions, and demotivation. She was admitted with catatonic stupor, staring and mutism. She improved with haloperidol, exhibiting severe distraction with thought block and hypersensitivity to background noise, before recalling visual/auditory hallucinations, confusion and delusions. In August 2008 she suffered a spontaneous popliteal vein thrombosis and a mild purpuric rash.

She had no personal or family history of psychiatric, autoimmune or thromboembolic disease, did not smoke or use recreational drugs, and took no medication except an oral contraceptive.

She had persistent elevations in alanine aminotransferase (79 U/L prior to quetiapine, peak 257 U/L), erythrocyte sedimentation rate (19–24 mm/h), and C-reactive protein (17 mg/l). Hepatic ultrasound showed mild diffuse echogenicity. Anticardiolipin antibodies were positive (22 IgM U/ml, August 2008; 25.4 IgG U/ml, October 2008; 18.0 IgM U/ml, November 2008 after immunosuppression). Antinuclear antibody was negative from 25.4 IgGU/ml, October 2008; 18.0 IgMU/ml, November 2008 after lipin antibodies were positive (22 IgMU/ml, August 2008; 40.0 IgGU/ml, October 2008). She was anticoagulated further (international normalised ratio 3:4) for the thrombosis.

She had no personal or family history of psychiatric, autoimmune or thromboembolic disease, did not smoke or use recreational drugs, and took no medication except an oral contraceptive.

She had persistent elevations in alanine aminotransferase (79 U/L prior to quetiapine, peak 257 U/L), erythrocyte sedimentation rate (19–24 mm/h), and C-reactive protein (17 mg/l). Hepatic ultrasound showed mild diffuse echogenicity. Anticardiolipin antibodies were positive (22 IgM U/ml, August 2008; 25.4 IgG U/ml, October 2008; 18.0 IgM U/ml, November 2008 after immunosuppression). Antinuclear antibody was negative from 25.4 IgGU/ml, October 2008; 18.0 IgMU/ml, November 2008 after lipin antibodies were positive (22 IgMU/ml, August 2008; 40.0 IgGU/ml, October 2008). She was anticoagulated further (international normalised ratio 3:4) for the thrombosis.

She had no personal or family history of psychiatric, autoimmune or thromboembolic disease, did not smoke or use recreational drugs, and took no medication except an oral contraceptive.

She had persistent elevations in alanine aminotransferase (79 U/L prior to quetiapine, peak 257 U/L), erythrocyte sedimentation rate (19–24 mm/h), and C-reactive protein (17 mg/l). Hepatic ultrasound showed mild diffuse echogenicity. Anticardiolipin antibodies were positive (22 IgM U/ml, August 2008; 25.4 IgG U/ml, October 2008; 18.0 IgM U/ml, November 2008 after immunosuppression). Antinuclear antibody was negative from 25.4 IgGU/ml, October 2008; 18.0 IgMU/ml, November 2008 after lipin antibodies were positive (22 IgMU/ml, August 2008; 40.0 IgGU/ml, October 2008). She was anticoagulated further (international normalised ratio 3:4) for the thrombosis.

She had no personal or family history of psychiatric, autoimmune or thromboembolic disease, did not smoke or use recreational drugs, and took no medication except an oral contraceptive.

She had persistent elevations in alanine aminotransferase (79 U/L prior to quetiapine, peak 257 U/L), erythrocyte sedimentation rate (19–24 mm/h), and C-reactive protein (17 mg/l). Hepatic ultrasound showed mild diffuse echogenicity. Anticardiolipin antibodies were positive (22 IgM U/ml, August 2008; 25.4 IgG U/ml, October 2008; 18.0 IgM U/ml, November 2008 after immunosuppression). Antinuclear antibody was negative from 25.4 IgGU/ml, October 2008; 18.0 IgMU/ml, November 2008 after lipin antibodies were positive (22 IgMU/ml, August 2008; 40.0 IgGU/ml, October 2008). She was anticoagulated further (international normalised ratio 3:4) for the thrombosis.

She had no personal or family history of psychiatric, autoimmune or thromboembolic disease, did not smoke or use recreational drugs, and took no medication except an oral contraceptive.

She had persistent elevations in alanine aminotransferase (79 U/L prior to quetiapine, peak 257 U/L), erythrocyte sedimentation rate (19–24 mm/h), and C-reactive protein (17 mg/l). Hepatic ultrasound showed mild diffuse echogenicity. Anticardiolipin antibodies were positive (22 IgM U/ml, August 2008; 25.4 IgG U/ml, October 2008; 18.0 IgM U/ml, November 2008 after immunosuppression). Antinuclear antibody was negative from 25.4 IgGU/ml, October 2008; 18.0 IgMU/ml, November 2008 after lipin antibodies were positive (22 IgMU/ml, August 2008; 40.0 IgGU/ml, October 2008). She was anticoagulated further (international normalised ratio 3:4) for the thrombosis.
Psychosis and catatonia as a first presentation of antiphospholipid syndrome
Rudolf N. Cardinal, Deepa N. Shah, Christopher J. Edwards, Graham R. V. Hughes and Emilio Fernández-Egea
Access the most recent version at DOI: 10.1192/bjp.195.3.272

References
This article cites 4 articles, 1 of which you can access for free at:
http://bjp.rcpsych.org/content/195/3/272#BIBL

Reprints/permissions
To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

You can respond to this article at
/letters/submit/bjprcpsych;195/3/272

Downloaded from
http://bjp.rcpsych.org/ on April 6, 2017
Published by The Royal College of Psychiatrists

To subscribe to The British Journal of Psychiatry go to:
http://bjp.rcpsych.org/site/subscriptions/